Humira, Remicade, Linked To Serious Infection Risks in Psoriasis Patients: Study

The side effects of Humira and Remicade, two popular rheumatoid arthritis and psoriasis drugs, may increase the risk of serious infections when used by certain patients, according to the findings of a new study.

In a report published this month in the medical journal JAMA Dermatology, French researchers warn that new users of Humira with psoriasis appear to face a 22% increased risk of serious infections, while Remicade users with psoriasis face a 79% increased infection risk, a study by French researchers found.

Humira and Remicade belong to a class of drugs known as tumor necrosis factor (TNF) blockers.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Humira (adalimumab) was approved by the FDA in 2003 for treatment of rheumatoid arthritis. It later gained approval for treatment of psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis, which was previously called juvenile rheumatoid arthritis. The drug pulled in sales of $6.5 billion in 2010.

Remicade was introduced in 1998, and is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, plaque psoriasis,, Crohn’s disease, ulcerative colitis, and ankylosing spondylitis.

In this latest study, researchers conducted a nationwide cohort study in France using data from the French National Health Data System, which has date on about 99% of that country’s population. They looked for data on all adults with psoriasis who received at least two prescriptions of a topical vitamin D derivative within a two year period between January 1, 2008 and May 31, 2019.

According to the findings, more than 44,000 new users of biologic treatments were identified in the study. According to the findings, the overall rate of serious infection was 25 per 1,000 person years. While a third TNF blocker, Enbrel, showed no association with an increased risk of serious infections, new Humira users were linked to a 22% increased risk of serious infections, and new Remicade users faced a 79% increased risk.

Gastrointestinal infections accounted for 38.9% of serious infections regardless of medication and were the most frequently reported. The simultaneous use of nonsteroidal anti-inflammatory drugs, like Advil and Motrin, or systemic corticosteroids, increased the infection risks.

“These results could help physicians choose a biologic for patients with psoriasis who are at risk of serious infections,” the researchers concluded.

1 Comments

  • NicoleMay 6, 2022 at 2:51 pm

    As a Patient I put on Remicade Infusion therapy from 2019-2020, ordered by my newly appointed GI doctor in Beverly Hills. Not only was I over 65 with pre-existing conditions prior starting the trial. I never was informed or received patient information and warnings about the drug Remicade, and why this only medication offered and I irrefutably ordered to be on. As of 5/5/22, I still no record [Show More]As a Patient I put on Remicade Infusion therapy from 2019-2020, ordered by my newly appointed GI doctor in Beverly Hills. Not only was I over 65 with pre-existing conditions prior starting the trial. I never was informed or received patient information and warnings about the drug Remicade, and why this only medication offered and I irrefutably ordered to be on. As of 5/5/22, I still no record of my medical confitions that deemed it a medical necessity for Remicade to be assigned and covered by insurance. The oversight & prescribing Physican for Remicode Infusions ceased to commicate upon initial Remicade infusion. Ehwre outsourced to a outside Oncologist in another who medical center without any explanation or details about what my plan of care was let alone was provide patient support or anyone to help. Once Remicade Infusion were authorised, all oversight my medical care stopped and didn’t consider me a patient of theirs. I was left abandoned & endangered as a patient immediately as I started developing acute side effects, and became so ill I couldn’t work, live independently without assistance, receive proper treatment, and follow up with appts, blood works, scans, calls, and ceased all affiliated medical physicians ceased communication and ongoing care with me. I am currently in the process of establishing care with new doctors to complete the initial exams and surgical procedures that were never completed. I’m also completely in the dark and need assistance on to navigate my life and medical are from this point forward. Remicade treatment physicians not only do not return or acknowledge my requests & information. Their negligence as providers who advocates for Remicade not only violated and their Physician Obligations and most importantly my patients rights, PHI, HIPPA, and overall safety & life. Please help me, my life will never be the same again.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.